Tirabrutinib

Tirabrutinib in the glossary for Waldenström's macroglobulinemia

A second generation small molecule inhibitor of Bruton's tyrosine kinase

Tirabrutinib is a selective, irreversible, second-generation, small-molecule BTK inhibitor. Oral tirabrutinib is approved in Japan for the treatment of recurrent or refractory primary central nervous system lymphoma. Tirabrutinib is also under regulatory review in Japan for the treatment of Waldenström's macroglobulinemia and lymphoplasmacytic lymphoma. Tirabrutinib is not licensed for use in the EU.¹

Glossary overview

References

1.Dhillon, S. Tirabrutinib: First Approval. Drugs 2020: 80(8);835-840.

This website contains information for a broad scientific audience and may include information on products or indications that are not licensed, approved, or accessible in your country or region. Prescribing information or other medical information for products may also differ between countries or regions. Please consult the appropriate national or regional regulatory authority for specific information on a product or indication included here.